The Drug-drug Interaction of SHR3824 and SP2086

Drug Interaction Study of Henagliflozin and Retagliptin in Healthy Subjects

The purpose of the study is to investigate the potential interaction between multiple oral doses of SHR3824 and multiple oral doses of SP2086 in healthy adult volunteers.

Study Overview

• Status: Unknown
• Conditions: Type 2 Diabetes
• Intervention / Treatment: Drug: SHR3824, SP2086

Detailed Description

This is an open-label (volunteers will know the names of treatments they are assigned) single-center study of SHR3824 and SP2086 in healthy adult volunteers. SHR3824(a Sodium-Glucose Cotransporter 2 inhibitor) is currently under development to lower blood sugar levels in patients with type 2 diabetes mellitus (T2DM) ,and SP2086(a Dipeptidyl peptidase IV inhibitor) is also currently under development to lower blood sugar levels in patients with type 2 diabetes mellitus (T2DM).SP2086 will be administered orally (by mouth) as 100mg on Days 1, 2, 3, 4, 15, 16, 17 and 18, SHR3824 will be administered orally (by mouth) as 20mg on Days 11, 12, 13, 14, 15, 16, 17 and 18. Both SHR3824 and SP2086 tablets will be taken with 8 ounces (240 mL) of water.

• Study Type: Interventional
• Enrollment (Anticipated): 12
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Haiyan Liu, PhD; Phone Number: +86-15705155025; Email: liuhaiyan@shhrp.com

Study Locations

• China
  • Hubei
    • Wuhan, Hubei, China
      • Recruiting
      • Phase I Unit of Tongji Hospital affilated Tongji Medical School of Huangzhong Science and Thechnology
      • Contact: Dong Liu, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 45 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Healthy volunteers with a body mass index (BMI, a measure of a person's weight in relation to height) between 19 and 24 kg/m2.

Exclusion Criteria:

• History of diabetes
• History of heart failure or renal insufficiency,Urinary tract infections, or vulvovaginal mycotic infections
• History of or current clinically significant medical illness as determined by the Investigator
• History of clinically significant allergies, especially known hypersensitivity or intolerance to lactose
• Known allergy to SHR3824 or SP2086 or any of the excipients of the formulation of SHR3824 or SP2086

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: SHR3824 20mg/SP2086 100mg; One 100-mg tablet of SP2086 once daily on Day 1,2,3,4 followed by two 10-mg tablets of SHR3824 once daily on Day 11,12,13,14, followed by one 100-mg tablet of SP2086 and two 10-mg tablets of SHR3824 on Day 15,16,17,18.	Drug: SHR3824, SP2086; One 100-mg tablet of SP2086 once daily on Day 1,2,3,4 followed by two 10-mg tablets of SHR3824 once daily on Day 11,12,13,14, followed by one 100-mg tablet of SP2086 and two 10-mg tablets of SHR3824 on Day 15,16,17,18.; Other Names: Henagliflozin, Retagliptin

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The maximum plasma concentration (Cmax) of SHR3824.	Cmax (a measure of the body's exposure to SHR3824) will be compared before and after administration of multiple doses of SP2086.	At protocol-specified times up to Day 14 and Day 18.
The area under the plasma concentration-time curve (AUC) of SHR3824.	AUC (a measure of the body's exposure to SHR3824) will be compared before and after administration of multiple doses of SP2086.	At protocol-specified times up to Day 14 and Day 18.
The maximum plasma concentration (Cmax) of SP2086.	Cmax (a measure of the body's exposure to SP2086) will be compared. before and after administration of multiple doses of SHR3824	At protocol-specified times up to Day 4 and Day 18.
The area under the plasma concentration-time curve (AUC) of SP2086.	AUC (a measure of the body's exposure to SP2086) will be compared before and after administration of multiple doses of SHR3824.	At protocol-specified times up to Day 4 and Day 18.
The number of volunteers with adverse events as a measure of safety and tolerability.		Up tp day 18.

Collaborators and Investigators

• Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Study record dates

Study Major Dates

• Study Start: May 1, 2015
• Primary Completion (Actual): July 1, 2015

Study Registration Dates

• First Submitted: July 14, 2015
• First Submitted That Met QC Criteria: July 14, 2015
• First Posted (Estimate): July 16, 2015

Study Record Updates

• Last Update Posted (Estimate): November 25, 2015
• Last Update Submitted That Met QC Criteria: November 23, 2015
• Last Verified: July 1, 2015

More Information

Terms related to this study

• Keywords: SHR3824 SP2086 drug-drug interaction
• Other Study ID Numbers: SHR3824-106